Kodiak Sciences Inc. Reports Increased Q1 2025 Net Loss of $57.5 Million, EPS Declines to $1.09

Reuters

2025/05/15

<a href="https://laohu8.com/S/KOD">Kodiak Sciences Inc.</a> Reports Increased Q1 2025 Net Loss of $57.5 Million, EPS Declines to $1.09

Kodiak Sciences Inc. reported its first quarter 2025 financial results, revealing a net loss of $57.5 million, or $1.09 per share, compared to a net loss of $43.0 million, or $0.82 per share, in the same period of 2024. The net loss for the quarter included non-cash stock-based compensation of $15.9 million, down from $18.4 million in the previous year. Kodiak ended the quarter with $138.9 million in cash and cash equivalents, which is expected to support its operations into 2026. The company highlighted its focus on progressing its pipeline, with plans to host an Investor R&D Update on July 16, 2025. This event will cover scientific, clinical, and commercial perspectives across its projects, including updates on several Phase 3 studies for treatments targeting diabetic retinopathy and wet AMD, as well as new data from a Phase 1b trial for KSI-101 in patients with Diabetic Macular Edema.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF88391) on May 14, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535007098"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535007098\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535007098?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-15 04:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535007098","market":"nz","top_or_hot":-1,"title":"Kodiak Sciences Inc. Reports Increased Q1 2025 Net Loss of $57.5 Million, EPS Declines to $1.09","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KOD\">Kodiak Sciences Inc.</a> Reports Increased Q1 2025 Net Loss of $57.5 Million, EPS Declines to $1.09\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kodiak Sciences Inc. reported its first quarter 2025 financial results, revealing a net loss of $57.5 million, or $1.09 per share, compared to a net loss of $43.0 million, or $0.82 per share, in the same period of 2024. The net loss for the quarter included non-cash stock-based compensation of $15.9 million, down from $18.4 million in the previous year. Kodiak ended the quarter with $138.9 million in cash and cash equivalents, which is expected to support its operations into 2026. The company highlighted its focus on progressing its pipeline, with plans to host an Investor R&amp;D Update on July 16, 2025. This event will cover scientific, clinical, and commercial perspectives across its projects, including updates on several Phase 3 studies for treatments targeting diabetic retinopathy and wet AMD, as well as new data from a Phase 1b trial for KSI-101 in patients with Diabetic Macular Edema.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF88391) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kodiak Sciences Inc. Reports Increased Q1 2025 Net Loss of $57.5 Million, EPS Declines to $1.09</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKodiak Sciences Inc. Reports Increased Q1 2025 Net Loss of $57.5 Million, EPS Declines to $1.09\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-15 04:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KOD\">Kodiak Sciences Inc.</a> Reports Increased Q1 2025 Net Loss of $57.5 Million, EPS Declines to $1.09\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kodiak Sciences Inc. reported its first quarter 2025 financial results, revealing a net loss of $57.5 million, or $1.09 per share, compared to a net loss of $43.0 million, or $0.82 per share, in the same period of 2024. The net loss for the quarter included non-cash stock-based compensation of $15.9 million, down from $18.4 million in the previous year. Kodiak ended the quarter with $138.9 million in cash and cash equivalents, which is expected to support its operations into 2026. The company highlighted its focus on progressing its pipeline, with plans to host an Investor R&amp;D Update on July 16, 2025. This event will cover scientific, clinical, and commercial perspectives across its projects, including updates on several Phase 3 studies for treatments targeting diabetic retinopathy and wet AMD, as well as new data from a Phase 1b trial for KSI-101 in patients with Diabetic Macular Edema.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF88391) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KOD","symbol_name":"Kodiak Sciences Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL72T5xB:1","article_id":"2535007098","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535007098","pubTimestamp":1747254272,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kodiak Sciences Inc. reported its first quarter 2025 financial results, revealing a net loss of $57.5 million, or $1.09 per share, compared to a net loss of $43.0 million, or $0.82 per share, in the same period of 2024. The net loss for the quarter included non-cash stock-based compensation of $15.9 million, down from $18.4 million in the previous year. Kodiak ended the quarter with $138.9 million in cash and cash equivalents, which is expected to support its operations into 2026. The company highlighted its focus on progressing its pipeline, with plans to host an Investor R&D Update on July 16, 2025. This event will cover scientific, clinical, and commercial perspectives across its projects, including updates on several Phase 3 studies for treatments targeting diabetic retinopathy and wet AMD, as well as new data from a Phase 1b trial for KSI-101 in patients with Diabetic Macular Edema.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"KOD":"Kodiak Sciences Inc."},"translate_title":"Kodiak Sciences Inc.报告2025年第一季度净亏损增加5750万美元，每股收益下降至1.09美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KOD":0.9},"content_text":"Kodiak Sciences Inc. Reports Increased Q1 2025 Net Loss of $57.5 Million, EPS Declines to $1.09\n    \n\n        Kodiak Sciences Inc. reported its first quarter 2025 financial results, revealing a net loss of $57.5 million, or $1.09 per share, compared to a net loss of $43.0 million, or $0.82 per share, in the same period of 2024. The net loss for the quarter included non-cash stock-based compensation of $15.9 million, down from $18.4 million in the previous year. Kodiak ended the quarter with $138.9 million in cash and cash equivalents, which is expected to support its operations into 2026. The company highlighted its focus on progressing its pipeline, with plans to host an Investor R&D Update on July 16, 2025. This event will cover scientific, clinical, and commercial perspectives across its projects, including updates on several Phase 3 studies for treatments targeting diabetic retinopathy and wet AMD, as well as new data from a Phase 1b trial for KSI-101 in patients with Diabetic Macular Edema.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF88391) on May 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}